transient receptor potential cation channel subfamily M member 5Genealiases: LTRPC5 · MTR1
Q-omics provides the consensus-scored TRPM5 profile across patient tissues and cancer cell-line models. TRPM5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRPM5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TRPM5 RNA expression shows 12,057 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where TRPM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPM5 survival associations across molecular data types. TRPM5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPM5 RNA expression–survival associations across cancer types. High TRPM5 expression shows unfavorable associations in KIRP, COAD, UCEC, ACC and LGG, but favorable associations in SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRPM5 RNA expression.
This table summarizes TRPM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRPM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPM5 shows lower tumor expression in KIRC, KICH, KIRP, THCA and COAD and higher tumor expression in LIHC. The KIRC box plot shows higher TRPM5 RNA expression in normal versus tumor tissue (log2 FC = −0.359, t-test p < 0.001).
This table shows molecular features associated with TRPM5 in patient tissues and cancer cell lines. In patient samples, TRPM5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
